1228690-20-7 Usage
General Description
The chemical (R)-1-(2-chlorophenyl)ethyl (5-(4-broMophenyl)-3-Methylisoxazol-4-yl)carbaMate, also known as eslicarbazepine acetate, is an anticonvulsant medication used to treat epilepsy. It works by stabilizing voltage-gated sodium channels in the brain, reducing the excessive electrical activity that can lead to seizures. Eslicarbazepine acetate is a prodrug, meaning it is inactive until it is metabolized into its active form in the body. It is commonly prescribed as an adjunctive therapy to other antiepileptic drugs for the management of partial-onset seizures. Eslicarbazepine acetate is marketed under the brand names Aptiom and Zebinix. Common side effects include dizziness, drowsiness, nausea, and fatigue. It is important to follow the prescribing doctor's instructions and to report any unusual or severe side effects.
Check Digit Verification of cas no
The CAS Registry Mumber 1228690-20-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,2,8,6,9 and 0 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1228690-20:
(9*1)+(8*2)+(7*2)+(6*8)+(5*6)+(4*9)+(3*0)+(2*2)+(1*0)=157
157 % 10 = 7
So 1228690-20-7 is a valid CAS Registry Number.
1228690-20-7Relevant articles and documents
LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS
-
, (2013/03/26)
Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.
POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS
-
Page/Page column 50, (2010/12/29)
Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.
